STOCK TITAN

Vericel - VCEL STOCK NEWS

Welcome to our dedicated page for Vericel news (Ticker: VCEL), a resource for investors and traders seeking the latest updates and insights on Vericel stock.

Vericel Corporation (VCEL) pioneers patient-specific cellular therapies for sports medicine and severe burn care through advanced regenerative science. This dedicated news hub provides investors and medical professionals with timely updates on the company’s progress in transforming treatment paradigms.

Access authoritative information on FDA approvals, clinical trial outcomes, and strategic initiatives shaping the future of cell-based therapies. Our curated collection includes:

- Quarterly earnings reports and financial disclosures
- Product launch announcements and manufacturing updates
- Research collaborations and intellectual property developments
- Regulatory milestones for novel treatment platforms

Bookmark this page for streamlined tracking of Vericel’s advancements in autologous cell therapies, including innovations in cartilage repair and burn wound management. Stay informed about developments that impact both patient care and investment considerations in the evolving biologics sector.

Rhea-AI Summary
Vericel Corporation (VCEL) executives to participate in a fireside chat at a healthcare conference. The webcast will be available on the company's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.17%
Tags
conferences
-
Rhea-AI Summary
Vericel Corporation (NASDAQ:VCEL) will report its Q4 and full-year 2023 financial results on February 29, 2024. The company will discuss financial results and business highlights in a conference call and webcast.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.81%
Tags
conferences earnings
-
Rhea-AI Summary
Vericel Corporation (VCEL) CEO to present at Canaccord Genuity Musculoskeletal Conference on February 12, 2024. The webcast will be available on the company's Investor Relations website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.77%
Tags
conferences
Rhea-AI Summary
Vericel Corporation (VCEL) Expects 20% Total Revenue Growth to $197.5M, 25% Growth in MACI Revenue, and 31% Growth in Burn Care Revenue in Fourth Quarter
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.24%
Tags
-
Rhea-AI Summary
Vericel Corporation (VCEL) to present at 42nd Annual J.P. Morgan Healthcare Conference. Webcast available on Investor Relations section of the Vericel Corporation website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.9%
Tags
conferences
-
Rhea-AI Summary
Vericel Corporation (NASDAQ:VCEL) reports record third quarter revenue of $45.6 million, an 18% growth versus the prior year. MACI revenue grew by 21% to $37.6 million. Full-year 2023 revenue guidance raised to $192.5-197.5 million. Positive results from NexoBrid Phase 3 DETECT study published in the Journal of Burn Care & Research.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.4%
Tags
Rhea-AI Summary
Vericel Corporation (NASDAQ:VCEL) will have its President and CEO and CFO present at the Stephens Annual Investment Conference on November 15, 2023. The webcast of the presentation will be available on the Investor Relations section of the Vericel Corporation website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1%
Tags
conferences
-
Rhea-AI Summary
Vericel Corporation (NASDAQ:VCEL) will report its third-quarter 2023 financial results on November 8, 2023. The company's management will host a conference call and webcast to discuss the results and business highlights.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.08%
Tags
conferences earnings
-
Rhea-AI Summary
Vericel Corporation announces positive results from Phase 3 DETECT study on NexoBrid treatment for severe burns, with over 90% of patients achieving complete eschar removal and reduced need for surgery.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.03%
Tags
Rhea-AI Summary
Vericel launches NexoBrid for eschar removal in burn patients, expanding market potential. NexoBrid offers faster and more precise removal of eschar, reducing need for skin grafting. Represents a paradigm shift in burn treatment. Market potential estimated at $300 million.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.14%
Tags
none
Vericel

Nasdaq:VCEL

VCEL Rankings

VCEL Stock Data

2.07B
49.62M
1.03%
106.6%
7.79%
Biotechnology
Biological Products, (no Disgnostic Substances)
Link
United States
CAMBRIDGE